UT
UTH.F United Therapeutics Corporation
- Market cap
- EUR 22.7B
- P/E
- 23.3x
- P/B
- 4.00x
- ROE
- 18.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is UTH.F undervalued?
Graham numberUTH.F trades 103.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
United Therapeutics Corporation fundamental analysis
No fundamental analysis for United Therapeutics Corporation yet.
United Therapeutics Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish sy…
Full company profileUnited Therapeutics Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
United Therapeutics Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.60B | 1.73B | 1.63B | 1.45B | 1.48B | 1.69B | 1.94B | 2.33B | 2.88B | 3.18B | 3.20B |
| Gross Profit | 1.53B | 1.62B | 1.43B | 1.33B | 1.38B | 1.56B | 1.78B | 2.07B | 2.57B | 2.80B | 2.75B |
| Operating Income | 1.06B | 1.02B | 805M | -188M | 594M | 556M | 980M | 1.18B | 1.45B | 1.52B | 1.20B |
| EBITDA | - | 810M | 809M | -74.9M | 712M | 662M | 983M | 1.39B | 1.65B | 1.82B | 1.53B |
| Net Income | 714M | 418M | 589M | -105M | 515M | 476M | 727M | 985M | 1.20B | 1.33B | 1.16B |
| EPS | - | 9.66 | 14 | -2.38 | 12 | 11 | 16 | 21 | 27 | 31 | 27 |
| Balance Sheet | |||||||||||
| Total Assets | 2.33B | 2.88B | 3.40B | 3.91B | 4.62B | 5.17B | 6.04B | 7.17B | 7.36B | 7.88B | 7.03B |
| Total Liabilities | 463M | 758M | 593M | 1.13B | 1.22B | 1.21B | 1.25B | 1.18B | 920M | 784M | 758M |
| Shareholders' Equity | 1.86B | 2.12B | 2.81B | 2.78B | 3.40B | 3.96B | 4.80B | 5.98B | 6.44B | 7.10B | 6.28B |
| Cash & Short-term Investments | 1.02B | 705M | 669M | 738M | 739M | 895M | 961M | 1.21B | 1.70B | 1.56B | 1.19B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 644M | 474M | 778M | -207M | 756M | 598M | 803M | 956M | 1.33B | 1.56B | 1.44B |
| Capital Expenditure | 43.2M | 86.3M | 184M | 83.7M | 59.3M | 121M | 139M | 191M | 247M | 526M | 519M |
| Free Cash Flow | - | 388M | 594M | -290M | 696M | 477M | 664M | 764M | 1.08B | 1.04B | 925M |
| Ratios | |||||||||||
| ROE | 38.3% | 19.7% | 21.0% | -3.8% | 15.2% | 12.0% | 15.2% | 16.5% | 18.5% | 18.8% | 18.4% |
| ROA | 30.7% | 14.5% | 17.3% | -2.7% | 11.2% | 9.2% | 12.0% | 13.7% | 16.2% | 16.9% | 16.4% |
| Net Profit Margin | 44.6% | 24.2% | 36.2% | -7.2% | 34.7% | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% | 36.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
United Therapeutics Corporation dividends
United Therapeutics Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Sep 23, 2009.
Who owns United Therapeutics Corporation
- Insiders 2.02%
- Institutions 97.98%
- Public & others 0.00%
- Shares outstanding 42.6M
- Free float 38.9M
United Therapeutics Corporation company profile
- Company name
- United Therapeutics Corporation
- Ticker
- UTH.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,400
- Fiscal year end
- December
- Address
- 1000 Spring Street, Silver Spring, MD, United States, 20910
- Phone
- 301 608 9292
- Website
- unither.com
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics Corporation management
9- Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.Founder, Chairman & CEO · born 1955
- Mr. Michael I. BenkowitzPresident & COO · born 1972
- Mr. James C. EdgemondCFO & Treasurer · born 1968
- Mr. Paul A. Mahon J.D.Executive VP, General Counsel & Corporate Secretary · born 1964
- Harrison SilversManager of Investor Relations
- Ms. Holly HobsonAssociate Vice President of Human Resources
- Mr. Patrick PoissonExecutive Vice President of Strategic Development · born 1968
- Dr. Leigh PetersonExecutive Vice President of Product Development & Xenotransplantation
- Mr. Gil Golden M.D., Ph.D.Senior VP, Chief Medical Officer & Member of the Scientific Advisory Board